Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., Aug.  28, 2020  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced that clinical data for its lead HBV core inhibitor vebicorvir (VBR, or ABI-H0731), its second-generation core inhibitor ABI-H2158, as well as its highly sensitive HBV assays were highlighted during The Digital International Liver Congress™(ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL).

Clinical Data from Assembly Biosciences’ HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 733.33% and 28.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Assembly Biosciences (ASMB) Surpasses Q2 Earnings and Revenue Estimates

SOUTH SAN FRANCISCO, Calif., Aug.  05, 2020  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results and recent highlights for the second quarter ended June 30, 2020.

Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

Assembly Biosciences (ASMB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assembly Biosciences (ASMB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

-- BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China --  -- Assembly receives $40 million upfront payment and is eligible to receive  up to $500 million in potential development, regulatory, and sales milestone payments plus royalties on product sales --  -- Assembly to host webcast and conference call today at 8:30 am ET --  SOUTH SAN FRANCISCO, Calif., BEIJING, China and CAMBRIDGE, Mass., July  20, 2020  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), today announced that the companies have entered into a collaboration in China for Assembly’s portfolio of three clinical-stage core inhibitor candidates for the treatment of patients with chronic hepatitis B virus (HBV) infection.

Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection

SOUTH SAN FRANCISCO, Calif., July  09, 2020  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABI-H2158 (2158) for the treatment of patients with chronic HBV infection. 2158 is Assembly’s second-generation core inhibitor, which is being evaluated in an ongoing global Phase 2 trial.

Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection

SOUTH SAN FRANCISCO, Calif., June  25, 2020  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the initiation of a Phase 2 trial of its potent, second-generation core inhibitor, ABI-H2158 (2158). The international multi-center, randomized, placebo-controlled trial will evaluate 2158 with entecavir versus placebo with entecavir in treatment-naïve patients with HBeAg positive chronic hepatitis B infection without cirrhosis.

Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection

Assembly Biosciences (ASMB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Assembly Biosciences (ASMB) Stock Stands Out in a Strong Industry

SOUTH SAN FRANCISCO, Calif., June  22, 2020  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that preclinical data from its immuno-oncology microbiome program are currently being featured in an e-poster at the  American Association for Cancer Research Virtual Annual Meeting II , June 22-24, 2020. The poster, Discovery and functional validation of a rationally selected, orally administered, live biotherapeutic consortium of commensal bacteria for the treatment of solid tumors, is also available in the Investors section of Assembly’s website:  https://investor.assemblybio.com/events-presentations .

Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting II

-- Process to explore strategic alternatives underway --   SOUTH SAN FRANCISCO, Calif., June  18, 2020  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that the Company will regain worldwide rights to all microbiome gastrointestinal programs licensed under its collaboration agreement with AbbVie (formerly Allergan pre-acquisition). AbbVie has decided to terminate the research, development, collaboration and license agreement. This decision was not based on any efficacy, safety, or other data related to the collaboration programs.

Assembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development Programs

Why Assembly Biosciences (ASMB) Stock Might be a Great Pick

As of late, it has definitely been a great time to be an investor Assembly Biosciences

Will Assembly Biosciences Continue to Surge Higher?

Assembly Biosciences, Inc. (ASMB) Assembly Biosciences' HBV Portfolio Progress Conference Call (Transcript)

SOUTH SAN FRANCISCO, Calif., March  31, 2020  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of inducement awards to its Chief Legal and Business Officer, Jason A. Okazaki on March 26, 2020.

Assembly Biosciences  Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.98% and 27.73%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Assembly Biosciences (ASMB) Reports Q4 Loss, Tops Revenue Estimates

SOUTH SAN FRANCISCO, Calif., Dec.  16, 2019  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public offering of 6,287,878 shares of its common stock to the public at $16.50 per share, which included the exercise in full by the underwriters of their option to purchase 1,136,363 additional shares of common stock. In addition, and in lieu of common stock, Assembly sold to a certain existing investor pre-funded warrants to purchase up to an aggregate of 2,424,242 shares of common stock at a purchase price of $16.499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds to Assembly from this offering were approximately $143.7 million, before deducting underwriting discounts and commissions and other offering expenses payable by Assembly. Assembly intends to use the net proceeds from the sale of the common stock to fund clinical trials, nonclinical studies, research and development and for general corporate purposes. 

Assembly Biosciences Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

An enthusiastic price for a secondary share offering lifted spirits and the stock.

Here's Why Assembly Biosciences Stock Is Soaring Today

SOUTH SAN FRANCISCO, Calif., Dec.  12, 2019  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 5,151,515 shares of its common stock to the public at $16.50 per share. In addition, and in lieu of common stock, Assembly is offering to a certain existing investor pre-funded warrants to purchase up to an aggregate of 2,424,242 shares of common stock at a purchase price of $16.499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The offering is expected to close on or about December 16, 2019, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to Assembly from this offering are expected to be approximately $125 million, before deducting underwriting discounts and commissions and other offering expenses payable by Assembly. Assembly has granted the underwriters a 30-day option to purchase up to an additional 1,136,363 shares of common stock at the offering price, less the underwriting discounts and commissions. Assembly intends to use the net proceeds from the sale of the common stock to fund clinical trials, nonclinical studies, research and development and for general corporate purposes. 

Assembly Biosciences Announces Pricing of $125 Million Public Offering

SOUTH SAN FRANCISCO, Calif., Dec.  11, 2019  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Assembly also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by Assembly. 

Assembly Biosciences Announces Proposed Public Offering of Common Stock

A Relative Strength Rating upgrade for Assembly Biosciences shows improving technical performance.

Stock Upgrades: Assembly Biosciences Shows Rising Relative Strength

SOUTH SAN FRANCISCO, Calif., Dec.  06, 2019  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Richard Colonno, PhD, Executive Vice President and Chief Scientific Officer Virology, will present a Plenary Lecture, “Eliminating Residual HBV Replication – A Critical Gateway to Cure” at the HEP DART Meeting on Tuesday, Dec 10, 2019 at 5:30pm HST in Kauai, HI. The presentation will include an in-depth review of interim long-term data from the ongoing Phase 2 study of ABI-H0731, Assembly’s lead core inhibitor, for the treatment of chronic Hepatitis B infection, which were reported at AASLD 2019 last month.

Assembly Biosciences Announces Plenary Lecture at HEP DART 2019

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals and Assembly Biosciences headed into an important industry meeting with rising share prices. Only one left the meeting with momentum intact.

2 Promising Hepatitis B Drugs, 1 Clear Winner Among Investors

SOUTH SAN FRANCISCO, Calif., Nov.  11, 2019  (GLOBE NEWSWIRE) --  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced that data for its first and second generation HBV core inhibitors were highlighted during today’s late-breaker poster session at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®) in Boston, Massachusetts. The posters featured final 24-week results and interim long-term data from the Phase 2 studies of ABI-H0731 (731). Additionally, the company presented initial data from the first dose cohort in the ongoing Phase 1b study of ABI-H2158 (2158). The posters will be made available on the Investors page of the assemblybio.com website.

Data for Assembly Biosciences’ First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2019

SOUTH SAN FRANCISCO, Calif., Nov.  07, 2019  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of inducement awards to its Chief Medical  Officer, Luisa M. Stamm, MD, PhD on November 6, 2019.

Assembly Biosciences (ASMB) Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov.  07, 2019  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Luisa Stamm, MD, PhD, as Chief Medical Officer. Dr. Stamm is an infectious disease specialist whose industry career has focused on the development of therapeutics for hepatitis C virus (HCV) and HIV.

News for Assembly Biosciences Stock (ASMB)